Ironwood Pharmaceuticals, Inc. - (IRWD): Price and Financial Metrics


Ironwood Pharmaceuticals, Inc. - (IRWD): $11.72

0.25 (+2.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

IRWD POWR Grades


  • Quality is the dimension where IRWD ranks best; there it ranks ahead of 99.71% of US stocks.
  • The strongest trend for IRWD is in Momentum, which has been heading down over the past 31 weeks.
  • IRWD ranks lowest in Momentum; there it ranks in the 5th percentile.

IRWD Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for IRWD is 3.62 -- better than 87.68% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 14.76 for Ironwood Pharmaceuticals Inc; that's greater than it is for 96.25% of US stocks.
  • The volatility of Ironwood Pharmaceuticals Inc's share price is greater than that of just 12.37% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Ironwood Pharmaceuticals Inc, a group of peers worth examining would be ZIXI, BHTG, TSC, MCF, and PHUN.
  • IRWD's SEC filings can be seen here. And to visit Ironwood Pharmaceuticals Inc's official web site, go to www.ironwoodpharma.com.

IRWD Price Target

For more insight on analysts targets of IRWD, see our IRWD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.67 Average Broker Recommendation 1.71 (Moderate Buy)

IRWD Stock Price Chart Interactive Chart >

Price chart for IRWD

IRWD Price/Volume Stats

Current price $11.72 52-week high $12.63
Prev. close $11.47 52-week low $8.63
Day low $11.37 Volume 3,585,800
Day high $11.76 Avg. volume 1,985,063
50-day MA $11.32 Dividend yield N/A
200-day MA $10.79 Market Cap 1.90B

Ironwood Pharmaceuticals, Inc. - (IRWD) Company Bio


Ironwood Pharmaceuticals engages in the research, development, and commercialization of human therapeutic products, with a key focus being the treatment of adult men and women suffering from irritable bowel syndrome. The company was founded in 1998 and is based in Cambridge, Massachusetts.


IRWD Latest News Stream


Event/Time News Detail
Loading, please wait...

IRWD Latest Social Stream


Loading social stream, please wait...

View Full IRWD Social Stream

Latest IRWD News From Around the Web

Below are the latest news stories about Ironwood Pharmaceuticals Inc that investors may wish to consider to help them evaluate IRWD as an investment opportunity.

Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

BOSTON, Jun 16, 2021--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that The American Journal of Gastroenterology – the official journal of The American College of Gastroenterology – published full results from the company’s Phase IIIb clinical trial evaluating LINZESS® (linaclotide) 290 mcg on multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation (IBS-C). The results, which can be viewed here, demonstrated

Yahoo | June 16, 2021

Top Pharmaceutical Stocks for Q3 2021

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q3 2021.

Yahoo | June 15, 2021

A Look At Ironwood Pharmaceuticals' (NASDAQ:IRWD) Share Price Returns

As an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock...

Yahoo | June 15, 2021

Ironwood Pharmaceuticals names Thomas McCourt permanent CEO

Ironwood Pharmaceuticals (IRWD) announces the appointment of Thomas McCourt, who has served as president and interim chief executive officer since March 12, 2021, as the company's permanent chief executive officer.McCourt has also been appointed to serve on Ironwood’s board, bringing the total number of directors to 11.Ironwood also announces that Gina Consylman plans to step down...

Seeking Alpha | June 7, 2021

Ironwood Pharmaceuticals Announces Leadership Updates

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the Board of Directors named Thomas McCourt, who has served as president and interim chief executive officer since March 12, 2021, as permanent chief executive officer. Mr. McCourt has also been appointed to serve on Ironwood’s Board. With the appointment of Mr. McCourt, the Board is now comprised of 11 directors.

Yahoo | June 7, 2021

Read More 'IRWD' Stories Here

IRWD Price Returns

1-mo -5.71%
3-mo 4.18%
6-mo -3.54%
1-year 21.96%
3-year -36.99%
5-year -7.86%
YTD 2.90%
2020 -14.43%
2019 28.47%
2018 -30.89%
2017 -1.96%
2016 31.92%

Continue Researching IRWD

Here are a few links from around the web to help you further your research on Ironwood Pharmaceuticals Inc's stock as an investment opportunity:

Ironwood Pharmaceuticals Inc (IRWD) Stock Price | Nasdaq
Ironwood Pharmaceuticals Inc (IRWD) Stock Quote, History and News - Yahoo Finance
Ironwood Pharmaceuticals Inc (IRWD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8421 seconds.